Week in review: FDA approvals, CRL for DEB, and more
Get caught up with our journal! Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.
Thank you for visiting the Contemporary Pediatrics® website. Take a look at some of our top stories from last week (Monday, April 22, to Friday, April 26, 2024), and click on each link to read and watch anything you may have missed.
1.) Ustekinumab biosimilar approved to treat moderate to severe plaque psoriasis
The biosimilar to ustekinumab is approved for patients 6 years and up, and is expected to be marketed on or after February 21, 2025.
Click here for the full article.
2.) CRL issued for pz-cel as potential recessive dystrophic epidermolysis bullosa treatment
Abeona's pz-cel is up for indicated use to treat patients with recessive dystrophic epidermolysis bullosa.
Click here for the full article.
3.) FDA approves tovorafenib for most common form of childhood brain tumor
This decision from the federal agency marks the first FDA approval of a systemic therapy to treat patients with pediatric LGG with BRAF rearrangements, including fusions.
Click here for the full article.
4.) First radioactive drug approved for patients 12 years and up with SSTR-positive GEP-NETs
The FDA has approved lutetium Lu 177 dotatate for pediatric patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.
Click here for the full article.
5.) Incorporating objective testing to add value to an ADHD diagnosis
Perry Roy, MD, explains how an FDA-cleared objective test can assist in an ADHD diagnosis.
"It's an objective test, so it adds value to the diagnosis," said Roy. "Currently, most methodologies for diagnosing ADHD is based on history. This [tool] is not replacing a good, accurate history. Other tools that have commonly been used and are certainly used are rating scales, which are quite subjective."
